Settings
Save and close
Antibodies are versatile tools for the treatment of diseases such as cancer, immunological disorders, and central nervous system (CNS) diseases. The creation and evaluation of antibody therapeutics requires sophisticated tools and in-depth expertise. JAX offers next-generation transgenic mice for monoclonal and bispecific antibody discovery, and a suite of humanized mouse models for the evaluation of pharmacokinetics, efficacy, and safety. Look to JAX for the best models and services to accelerate your antibody discovery programs.
Transgenic mice for monoclonal, bispecific, and multispecific antibody discovery.
Translational data from PDX, cell lines, humanized CD34+/PBMC mice, and genetically engineered models.
Test optimal dosage and cytokine response based on unique PBMC profiles.
We offer specialized models designed to generate antibodies with the desired diversity, developability, and affinity required to accelerate your antibody discovery programs and bring life-saving therapeutics into the clinic faster.
JAX has partnered with AbTherx to offer new transgenic platforms for monoclonal, bispecific and multispecific antibody discovery. We've combined our decades of experience in transgenic mice with AbTherx's deep knowledge in antibody discovery to help you create the next generation of antibody therapeutics.
Get the most clinically translational PK data for your antibody with JAX’s genetically-humanized FcRn platforms and move to the clinic faster. Work with us to find a model that suits your therapeutic’s configuration and immunogenicity and determine your ideal first-in-human dose.
Leverage JAX’s unrivaled NSG® mice engrafted with human PBMCs to examine donor-to-donor differences and engage human-specific targets.
Select from our range of immune-humanized mouse models to ensure the right immune cell populations for your therapeutic’s mode of action. Then test the safety and efficacy of your antibody in the presence or absence of a PDX or CDX tumor.
